Management of Angiotensin Inhibitors During the Perioperative Period
NCT04506372 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 342
Last updated 2023-11-29
Summary
This is a multicenter randomized clinical trial to determine the effect of continuation versus withdrawal of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in the perioperative period on postoperative complications.
Conditions
- Surgery
- Angiotensin Hypertension
- Perioperative Complication
Interventions
- DRUG
-
Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers
Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
- DIAGNOSTIC_TEST
-
Blood draw
Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
- BEHAVIORAL
-
Diary to register drug adherence
To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
- BEHAVIORAL
-
Quality of life questionnaire
Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
- BEHAVIORAL
-
WHODAS questionnaire
Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
Sponsors & Collaborators
-
ZonMw: The Netherlands Organisation for Health Research and Development
collaborator OTHER -
UMC Utrecht
lead OTHER
Principal Investigators
-
Judith van Waes, MD PhD · UMC Utrecht
-
Wilton van Klei, MD PhD · UMC Utrecht
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-11
- Primary Completion
- 2023-02-06
- Completion
- 2023-09-01
Countries
- Canada
- Netherlands
Study Locations
More Related Trials
-
Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects
NCT03001271 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Different Antihypertensive Drugs on Aortic Diseases
NCT06626607 ·Status: COMPLETED
-
Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives
NCT04531124 ·Status: NOT_YET_RECRUITING
-
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
NCT00605072 ·Status: COMPLETED ·Phase: PHASE2
-
Early Vascular Adjustments During Hypertensive Pregnancy
NCT02531490 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure
NCT00452049 ·Status: UNKNOWN
-
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
NCT01658657 ·Status: COMPLETED ·Phase: NA
-
Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial)
NCT02268071 ·Status: COMPLETED ·Phase: NA
-
Antihypertensive Drug Selection Based on Hemodynamic Phenotypes
NCT07240909 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population
NCT00966199 ·Status: UNKNOWN ·Phase: PHASE4
-
Angiotensin 1-7 in Obesity Hypertension
NCT03604289 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Vascular Dysfunction in Hypertensive Postmenopausal Women
NCT03371823 ·Status: TERMINATED ·Phase: PHASE4
-
Changes in Measured Plasma Volume, Glycocalyx and Atrial Natriuretic Peptide During Anaesthesia
NCT02832596 ·Status: COMPLETED ·Phase: NA
-
Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study
NCT00535808 ·Status: COMPLETED ·Phase: PHASE2
-
Nitroglycerine Versus Dexmedetomidine Infusion in Intraoperative Management of Uncontrolled Hypertension
NCT04953156 ·Status: COMPLETED
-
Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
NCT00742066 ·Status: UNKNOWN ·Phase: NA
-
Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)
NCT05275907 ·Status: WITHDRAWN ·Phase: PHASE4
-
Intensive Vasodilator Therapy in Patients With Essential Hypertension
NCT01180413 ·Status: COMPLETED ·Phase: PHASE4
-
Mechanisms of Anti-VEGF Induced Hypertension
NCT02156310 ·Status: COMPLETED
-
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
NCT05529147 ·Status: COMPLETED
-
Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism
NCT04991961 ·Status: COMPLETED
-
Accomplices of Insulin Resistance in Prehypertension: Aldosterone?
NCT01112007 ·Status: COMPLETED
-
Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension
NCT01850901 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Diabetes and Hypertension
NCT00456963 ·Status: TERMINATED ·Phase: PHASE4
-
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
NCT02245230 ·Status: TERMINATED ·Phase: PHASE1